Diabetic Foot Ulcer

The global incidence of diabetic foot ulcers has been estimated to be 6.3 percent. From 19 to 34 percent of persons with diabetes are likely to be affected by diabetic foot ulcers during their lifetime1. Furthermore, approximately 50 percent of the ulcers will become infected requiring hospitalization and it has been reported that 20 percent of the lower extremity infections will result in amputation2. Mortality rates are very high after amputation with up to 70 percent of people dying within 5 years3.

RLS Global’s overall goal is to provide a gentle and effective debridement method that results in improved care for healthcare professionals reducing the suffering for patients and the overall cost for the society in treating complicated wounds.

ChloraSolv has been evaluated on infected chronic diabetic foot ulcers in an open randomized controlled study where safety and tolerability were assessed as well as a beneficial outcome on wound size reduction and wound closure4.

ChloraSolv®

ChloraSolv has been developed to treat Infected Chronic Diabetic Foot Ulcers. To meet the needs to facilitate removal of  devitalized tissue preserving healthy, viable tissue during debridement.

Read more about ChloraSolv
  1. Armstrong et al. Diabetic Foot ulcers and their recurrence. N Eng J Med June 2017
  2. Clinical Practice Recommendations on the Diabetic Foot: A guide for health care professionals. International Diabetes Federation; 2017.
  3. Diabetic foot problems: prevention and management. National Institute for Health and Care Excellence, UK; 2015.
  4. Bergqvist K, Almhojd U, Herrmann I, Eliasson B. The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial. Clin Diabetes Endocrinol. 2016;2:6